Lethality and pathogenesis of airborne infection with filoviruses in A129 α/β -/- interferon receptor-deficient mice

被引:46
作者
Lever, Mark S. [1 ]
Piercy, Timothy J. [1 ]
Steward, Jackie A. [1 ]
Eastaugh, Lin [1 ]
Smither, Sophie J. [1 ]
Taylor, Christopher [1 ]
Salguero, Francisco J. [2 ]
Phillpotts, Robert J. [1 ]
机构
[1] Def Sci & Technol Labs, Salisbury SP4 0JQ, Wilts, England
[2] Vet Labs Agcy Weybridge, Dept Pathol, Addlestone KT15 3NB, Surrey, England
关键词
MOUSE MODEL; GUINEA-PIGS; EBOLA; MONKEYS; DISEASE; THERAPY; VIRUS;
D O I
10.1099/jmm.0.036210-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Normal immunocompetent mice are not susceptible to non-adapted filoviruses. There are therefore two strategies available to establish a murine model of filovirus infection: adaptation of the virus to the host or the use of genetically modified mice that are susceptible to the virus. A number of knockout (KO) strains of mice with defects in either their adaptive or innate immunity are susceptible to non-adapted filoviruses. In this study, A129 alpha/beta -/- interferon receptor-deficient KO mice, strain A129 IFN-alpha/beta -/-, were used to determine the lethality of a range of filoviruses, including Lake Victoria marburgvirus (MARV), Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Reston ebolavirus (REBOV) and Cote d'Ivoire ebolavirus (CIEBOV), administered by using intraperitoneal (IP) or aerosol routes of infection. One hundred percent mortality was observed in all groups of KO mice that were administered with a range of challenge doses of MARV and ZEBOV by either IP or aerosol routes. Mean time to death for both routes was dose-dependent and ranged from 5.4 to 7.4 days in the IP injection challenge, and from 10.2 to 13 days in the aerosol challenge. The lethal dose (50 % tissue culture infective dose, TCID50) of ZEBOV for KO mice was <1 TCID50 ml(-1) when administered by either the IP or aerosol route of infection; for MARV the lethal dose was <1 TCID50 ml(-1) by the IP route of infection and <10 TCID50 ml(-1) by the aerosol route. In contrast, there was no mortality after infection with SEBOV or REBOV by either IP or aerosol routes of infection; all the mice lost weight (similar to 15% loss of group mean body weight with SEBOV and similar to 7% with REBOV) but recovered to their original weights by day 14 post-challenge. There was no mortality in mice administered with CIEBOV via the IP route of infection and no clinical signs of infection were observed. The progression of disease was faster following infection with ZEBOV than with MARV but ultimately both viruses caused widespread infection with high titres of the infectious viruses in multiple organs. Histopathological observations were consistent with other animal models and showed widespread organ damage. This study suggests that MARV and ZEBOV are more virulent when administered via the IF route rather than by aerosol infection, although both are highly virulent by either route. The KO mouse may provide a useful model to test potential antiviral therapeutics against wild-type filoviruses.
引用
收藏
页码:8 / 15
页数:8
相关论文
共 29 条
  • [1] [Anonymous], 2009, Wkly Epidemiol Rec, V84, P49
  • [2] Discovery of Swine as a Host for the Reston ebolavirus
    Barrette, Roger W.
    Metwally, Samia A.
    Rowland, Jessica M.
    Xu, Lizhe
    Zaki, Sherif R.
    Nichol, Stuart T.
    Rollin, Pierre E.
    Towner, Jonathan S.
    Shieh, Wun-Ju
    Batten, Brigid
    Sealy, Tara K.
    Carrillo, Consuelo
    Moran, Karen E.
    Bracht, Alexa J.
    Mayr, Gregory A.
    Sirios-Cruz, Magdalena
    Catbagan, Davinio P.
    Lautner, Elizabeth A.
    Ksiazek, Thomas G.
    White, William R.
    McIntosh, Michael T.
    [J]. SCIENCE, 2009, 325 (5937) : 204 - 206
  • [3] BAZHUTIN NB, 1992, VOP VIRUSOL+, V37, P153
  • [4] Disease modeling for Ebola and Marburg viruses
    Bente, Dennis
    Gren, Jason
    Strong, James E.
    Feldmann, Heinz
    [J]. DISEASE MODELS & MECHANISMS, 2009, 2 (1-2) : 12 - 17
  • [5] A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
    Bray, M
    Davis, K
    Geisbert, T
    Schmaljohn, C
    Huggins, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) : 651 - 661
  • [6] Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus
    Bray, M
    Hatfill, S
    Hensley, L
    Huggins, JW
    [J]. JOURNAL OF COMPARATIVE PATHOLOGY, 2001, 125 (04) : 243 - 253
  • [7] Experimental therapy of filovirus infections
    Bray, M
    Paragas, J
    [J]. ANTIVIRAL RESEARCH, 2002, 54 (01) : 1 - 17
  • [8] The role of the Type I interferon response in the resistance of mice to filovirus infection
    Bray, M
    [J]. JOURNAL OF GENERAL VIROLOGY, 2001, 82 : 1365 - 1373
  • [9] Bray Mike, 2002, P875
  • [10] *CDC, 2009, CDC EM PREP RESP WEB